Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.

Pauthner MG, Nkolola JP, Havenar-Daughton C, Murrell B, Reiss SM, Bastidas R, Prévost J, Nedellec R, von Bredow B, Abbink P, Cottrell CA, Kulp DW, Tokatlian T, Nogal B, Bianchi M, Li H, Lee JH, Butera ST, Evans DT, Hangartner L, Finzi A, Wilson IA, Wyatt RT, Irvine DJ, Schief WR, Ward AB, Sanders RW, Crotty S, Shaw GM, Barouch DH, Burton DR.

Immunity. 2019 Jan 15;50(1):241-252.e6. doi: 10.1016/j.immuni.2018.11.011. Epub 2018 Dec 11.

2.

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Feb;79(3):1452-62.

3.

HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.

Wang Y, O'Dell S, Turner HL, Chiang CI, Lei L, Guenaga J, Wilson R, Martinez-Murillo P, Doria-Rose N, Ward AB, Mascola JR, Wyatt RT, Karlsson Hedestam GB, Li Y.

J Virol. 2017 Oct 13;91(21). pii: e00910-17. doi: 10.1128/JVI.00910-17. Print 2017 Nov 1.

4.

Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.

Burton SL, Kilgore KM, Smith SA, Reddy S, Hunter E, Robinson HL, Silvestri G, Amara RR, Derdeyn CA.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10780-5. doi: 10.1073/pnas.1509731112. Epub 2015 Aug 10.

5.

Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Lakhashe SK, Byrareddy SN, Zhou M, Bachler BC, Hemashettar G, Hu SL, Villinger F, Else JG, Stock S, Lee SJ, Vargas-Inchaustegui DA, Cofano EB, Robert-Guroff M, Johnson WE, Polonis VR, Forthal DN, Loret EP, Rasmussen RA, Ruprecht RM.

Vaccine. 2014 Nov 12;32(48):6527-36. doi: 10.1016/j.vaccine.2014.08.065. Epub 2014 Sep 20.

6.

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.

Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM.

Retrovirology. 2014 Jan 20;11:8. doi: 10.1186/1742-4690-11-8.

7.

A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B, Srivastava IK, Titti F, Cafaro A, Barnett SW, Ensoli B.

Vaccine. 2011 Apr 5;29(16):2918-32. doi: 10.1016/j.vaccine.2011.02.006. Epub 2011 Feb 21.

PMID:
21338681
8.

Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.

Siddappa NB, Hemashettar G, Wong YL, Lakhashe S, Rasmussen RA, Watkins JD, Novembre FJ, Villinger F, Else JG, Montefiori DC, Ruprecht RM.

J Med Primatol. 2011 Apr;40(2):120-8. doi: 10.1111/j.1600-0684.2010.00454.x. Epub 2010 Nov 2.

9.

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, Zur Megede J, Polo J, Donnelly J, Ulmer J, Otten GR, Miller CJ, Vajdy M, Srivastava IK.

J Virol. 2010 Jun;84(12):5975-85. doi: 10.1128/JVI.02533-09. Epub 2010 Apr 14.

10.

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.

Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, Dodd J, Dean H, Sattentau Q, Montefiori D, Klasse PJ, Sanders RW, Moore JP, Hanke T.

PLoS One. 2017 Aug 9;12(8):e0181886. doi: 10.1371/journal.pone.0181886. eCollection 2017.

11.

Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus.

Himeno A, Ishida Y, Mori H, Matsuura K, Kikukawa M, Sakawaki H, Miura T.

Arch Virol. 2019 May;164(5):1297-1308. doi: 10.1007/s00705-019-04173-5. Epub 2019 Feb 28.

PMID:
30820667
12.

Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.

Willey R, Nason MC, Nishimura Y, Follmann DA, Martin MA.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):89-98. doi: 10.1089/aid.2009.0144.

13.

R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.

Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, Kramer VG, Lakhashe S, Santosuosso M, Poznansky MC, Novembre FJ, Villinger F, Else JG, Montefiori DC, Rasmussen RA, Ruprecht RM.

PLoS One. 2010 Jul 21;5(7):e11689. doi: 10.1371/journal.pone.0011689.

15.

Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers.

Ringe RP, Ozorowski G, Rantalainen K, Struwe WB, Matthews K, Torres JL, Yasmeen A, Cottrell CA, Ketas TJ, LaBranche CC, Montefiori DC, Cupo A, Crispin M, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP.

J Virol. 2017 Jul 12;91(15). pii: e00677-17. doi: 10.1128/JVI.00677-17. Print 2017 Aug 1.

16.

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R, Patterson LJ, Korioth-Schmitz B, Buzby A, Dombagoda D, Montefiori DC, Letvin NL, Cafaro A, Ensoli B, Robert-Guroff M.

J Virol. 2007 Apr;81(7):3414-27. Epub 2007 Jan 17.

17.

Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.

Cheng C, Pancera M, Bossert A, Schmidt SD, Chen RE, Chen X, Druz A, Narpala S, Doria-Rose NA, McDermott AB, Kwong PD, Mascola JR.

J Virol. 2015 Dec 30;90(6):2740-55. doi: 10.1128/JVI.02380-15.

18.

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA.

Clin Vaccine Immunol. 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11. Review.

19.

Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.

Sundling C, O'Dell S, Douagi I, Forsell MN, Mörner A, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

J Virol. 2010 Sep;84(18):9086-95. doi: 10.1128/JVI.01015-10. Epub 2010 Jul 7.

20.

Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease.

Fultz PN, Stallworth J, Porter D, Novak M, Anderson MJ, Morrow CD.

Virology. 2003 Oct 25;315(2):425-37.

Supplemental Content

Support Center